Redbiotec AG produces recombinant proteins, protein complexes and virus-like particles for the use as novel vaccines and biologics. These protein assemblies are produced using Redbiotec’s proprietary protein co-expression platform (rePAX® technology). Our main focus is the generation of vaccine products to prevent Herpesvirus infections. Redbiotec also has an oncology program. Redbiotec AG was founded in 2006 as spin-off from the ETH Zürich and is located in the BIO-TECHNOPARK Schlieren-Zürich in Switzerland. For more information please visit www.redbiotec.ch.